Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.44 |
| ▸ | DCAF1 | Q9Y4B6 | 1/20 | 0.43 |
| ▸ | CTSV | O60911 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 9/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21410955 | 1.00 | CTSL (0.44) | CTSLDCAF1CTSVCTSSCTSK | |
| SCHEMBL21854245 | 0.92 | CAPN1 (0.51) | DCAF1CTSSCAPN1 | |
| SCHEMBL20027555 | 0.92 | CAPN1 (0.51) | DCAF1CTSSCAPN1 | |
| SCHEMBL22885972 | 0.91 | CTSL (0.42) | CTSLDCAF1CTSVCTSSCTSK | |
| SCHEMBL22886525 | 0.89 | CAPN1 (0.41) | CTSLCTSSPSMB5CAPN1 | |
| SCHEMBL22886498 | 0.88 | L3MBTL1 (0.46) | CTSLDCAF1CTSVCTSSCTSK | |
| SCHEMBL22886500 | 0.87 | DCAF1 (0.54) | CTSLDCAF1CTSVCTSSCTSK | |
| SCHEMBL22885813 | 0.86 | CAPN1 (0.40) | CTSSPSMB5CAPN1 | |
| SCHEMBL22886747 | 0.85 | CAPN1 (0.49) | CTSLDCAF1CTSVCTSSCTSK | |
| SCHEMBL20027556 | 0.85 | CAPN1 (0.48) | DCAF1CTSSPSMB5CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220347173-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | BLADE THERAPEUTICS INC (US) | 2022-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220347173-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | CAPNS1, CAPN9, CAPN2 | CTSL 54/4885DCAF1 3032/4885CTSV 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.